AU3095600A - New pharmaceutical formulation - Google Patents
New pharmaceutical formulation Download PDFInfo
- Publication number
- AU3095600A AU3095600A AU30956/00A AU3095600A AU3095600A AU 3095600 A AU3095600 A AU 3095600A AU 30956/00 A AU30956/00 A AU 30956/00A AU 3095600 A AU3095600 A AU 3095600A AU 3095600 A AU3095600 A AU 3095600A
- Authority
- AU
- Australia
- Prior art keywords
- physical form
- methyl
- physical
- amino
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9902742A SE9902742D0 (sv) | 1999-07-20 | 1999-07-20 | New pharmaceutical formultion |
SE9902742 | 1999-07-20 | ||
PCT/SE1999/002474 WO2001005376A1 (fr) | 1999-07-20 | 1999-12-22 | Nouvelle formulation pharmaceutique |
Publications (1)
Publication Number | Publication Date |
---|---|
AU3095600A true AU3095600A (en) | 2001-02-05 |
Family
ID=20416534
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU30956/00A Abandoned AU3095600A (en) | 1999-07-20 | 1999-12-22 | New pharmaceutical formulation |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP1113786A1 (fr) |
JP (1) | JP2003504392A (fr) |
KR (1) | KR20010078703A (fr) |
CN (1) | CN1319004A (fr) |
AU (1) | AU3095600A (fr) |
CA (1) | CA2328102A1 (fr) |
NO (1) | NO20004816L (fr) |
SE (1) | SE9902742D0 (fr) |
WO (1) | WO2001005376A1 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030211149A1 (en) * | 2002-05-07 | 2003-11-13 | Sherman Bernard Charles | Extended release tablets comprising felodipine |
GB0222612D0 (en) * | 2002-09-30 | 2002-11-06 | Univ Gent | Controlled delivery system for bioactive substances |
PL1812072T3 (pl) * | 2004-11-17 | 2009-04-30 | Ares Trading Sa | Benzotiazolowe formulacje oraz ich zastosowanie |
CN101103964B (zh) * | 2006-07-14 | 2010-09-29 | 海南盛科生命科学研究院 | 一种含有非洛地平的缓释制剂及其制备方法 |
KR100841877B1 (ko) * | 2006-08-31 | 2008-06-27 | 조선대학교산학협력단 | 국소적으로 가용화 된 난용성 약물의 제어 방출형 제제조성물 및 그의 제조 방법 |
CN102784128B (zh) * | 2012-07-31 | 2015-01-07 | 北京协和药厂 | 一种非洛地平缓释制剂及其制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE8601624D0 (sv) * | 1986-04-11 | 1986-04-11 | Haessle Ab | New pharmaceutical preparations |
DE3738236A1 (de) * | 1987-11-11 | 1989-05-24 | Euro Celtique Sa | Beisskapsel |
US5773025A (en) * | 1993-09-09 | 1998-06-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems--amorphous drugs |
IE80467B1 (en) * | 1995-07-03 | 1998-07-29 | Elan Corp Plc | Controlled release formulations for poorly soluble drugs |
ATE232087T1 (de) * | 1997-10-27 | 2003-02-15 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
-
1999
- 1999-07-20 SE SE9902742A patent/SE9902742D0/xx unknown
- 1999-12-22 WO PCT/SE1999/002474 patent/WO2001005376A1/fr not_active Application Discontinuation
- 1999-12-22 EP EP99964928A patent/EP1113786A1/fr not_active Withdrawn
- 1999-12-22 CA CA002328102A patent/CA2328102A1/fr not_active Abandoned
- 1999-12-22 JP JP2001510433A patent/JP2003504392A/ja active Pending
- 1999-12-22 KR KR1020007011312A patent/KR20010078703A/ko not_active Application Discontinuation
- 1999-12-22 CN CN99811100A patent/CN1319004A/zh active Pending
- 1999-12-22 AU AU30956/00A patent/AU3095600A/en not_active Abandoned
-
2000
- 2000-09-26 NO NO20004816A patent/NO20004816L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2001005376A1 (fr) | 2001-01-25 |
CN1319004A (zh) | 2001-10-24 |
CA2328102A1 (fr) | 2001-01-20 |
NO20004816L (no) | 2000-11-02 |
EP1113786A1 (fr) | 2001-07-11 |
NO20004816D0 (no) | 2000-09-26 |
SE9902742D0 (sv) | 1999-07-20 |
KR20010078703A (ko) | 2001-08-21 |
JP2003504392A (ja) | 2003-02-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2319308C (fr) | Agents pharmaceutiques | |
JP4282092B2 (ja) | 多形性化合物 | |
CA2056067C (fr) | Une forme physique de n-¬4-¬5-(cyclopentyloxcarbony)amino-1-methylindol-3-yl-methyi|-3-methoxybenzoy1|-2-methyibezenesulphonanide, procedes de preparation et les compositions les contenant | |
JP2022000451A (ja) | ピリジノイルピペリジン5−ht1fアゴニストに関する組成物および方法 | |
AU3095600A (en) | New pharmaceutical formulation | |
JPS6231714B2 (fr) | ||
US20080255231A1 (en) | Polymorphs of rivastigmine hydrogentartrate | |
JPH10182640A (ja) | ドキサゾシン・メシレートの新規な形態ii | |
FI106021B (fi) | Menetelmä N-[4-[5-(syklopentyylioksikarbonyyli)amino-1-metyyli-indol-3-yyli-metyyli]-3-metoksibentsoyyli]-2-metyylibentseenisulfonamidin fysikaalisen muodon valmistamiseksi | |
NO179575B (no) | Farmasöytisk preparat inneholdende en fysikalsk form av forbindelsen N-[4-[5-(cyklopentyloksykarbonyl)amino-1-metylindol-3-ylmetyl-3-metoksybenzoylÅ-2-metylbenzensulfonamid | |
WO2021097650A1 (fr) | Cocristal d'orlistat et d'acide aminé, et composition pharmaceutique le comprenant | |
PT100508B (pt) | Composicoes farmaceuticas e processo para a sua preparacao | |
SK7362002A3 (en) | Solid pharmaceutical preparation | |
HU220769B1 (hu) | N-[ 4-(5-/Ciklopentil-oxi-karbonil-amino/-l-metil-indol-3-il-metil)-3-metoxi-benzoil]-2-metil-benzolszulfonamid új fizikai módosulata és eljárás annak előállítására | |
MXPA00007921A (en) | Novel galenic formulations of meloxicam for oral administration | |
WO2009143767A1 (fr) | Co-cristaux d’atorvastatine hémi-calcium et de butanone, leurs procédés de préparation et leurs utilisations en tant qu’inhibiteur de l’enzyme hmg-coa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |